再談減除白血球血小板的好處

• Published in: 台灣醫學 Vol. 23; no. 6; pp. 785 - 788
• Main Authors: 林東燦(Dong-Tsamn Lin), 羅仕錡(Shyh-Chyi Lo)
• Format: Journal Article
• Language: Chinese
• Published: 台灣 臺灣醫學會 25.11.2019
• Subjects: cytomegalovirus; leukocyte-reduced platelets; non-hemolytic febrile transfusion reactions; platelet transfusion refractoriness; transfusion reaction; TSCI; 巨細胞病毒; 減除白血球血小板; 血小板輸注無效; 輸血不良反應; 非溶血性發熱性輸血反應; cytomegalovirus; 減除白血球血小板; 輸血不良反應; 血小板輸注無效; 巨細胞病毒; platelet transfusion refractoriness; leukocyte-reduced platelets; 非溶血性發熱性輸血反應; transfusion reaction; non-hemolytic febrile transfusion reactions
• ISSN: 1028-1916
• DOI: 10.6320/FJM.201911_23(6).0013

Substantial reports showed the evidenced-based effect of transfusion of leuko-reduced platelet concentrates (LRPC) including reduction of non-hemolytic febrile transfusion adverse reaction (NHFTR), CMV infection and prevention of occurrence of platelet transfusion refractoriness. Therefore, LRPC rather than platelet concentrates can improve transfusion safety definitely. Cost evaluation revealed that using LRPC can reduce total fee in dealing with NHFTR. In addition, another study showed that transfusion of LRPC can decrease the cost of management of platelet transfusion refractoriness dramatically. In this moment, we call for releasing or completely eliminating the limitation on the use of LRPC to create a win-win situation in Taiwan.
研究顯示輸注減除白血球血小板（減白血小板）可有效降低非溶血性發熱性輸血不良反應、巨細胞病毒感染及預防血小板輸注無效的發生，足以提昇輸血安全。此外，研究評估使用減白血小板可減少輸血不良反應的處置費用，更可以大幅降低因血小板輸注無效導致的血品費用。是以呼籲在台灣應放寬或解除輸用減白血小板的限制，以創造雙臝的局面